Nikolaos Antonakos

Clarithromycin in community-acquired pneumonia: a within-trial cost analysis of the ACCESS randomised, double-blind, placebo-controlled study

Community-acquired pneumonia (CAP) remains one of the leading infectious causes of morbidity, mortality, and healthcare expenditure worldwide. Combination therapy with a β-lactam/macrolide antibiotic is widely recommended, but there has been little investigation of the cost conse...